๐๏ธ Verified NIH Record โข Updated 2026-06-19
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer (NCT02750358)
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR(+) Triple Negative Breast Cancer
๐ต Active, Not Recruiting Phase2 ๐ Investigational Drug / Biologic Sponsor: Memorial Sloan Kettering Cancer Center
๐ฉบ Plain-English Summary (8th-Grade Level)
This trial is designed to determine the feasibility of 1 year of adjuvant enzalutamide, an androgen receptor (AR) antagonist for the treatment of patients with early stage, AR(+) triple negative breast cancer (TNBC).
Who can join: Review the eligibility criteria below.
Location: Hartford Healthcare Cancer Institute @ Hartford Hospital โ Hartford, Connecticut
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (12 Sites)
- Hartford Healthcare Cancer Institute @ Hartford Hospital โ Hartford, Connecticut
- Memorial Sloan Kettering Basking Ridge โ Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth โ Middletown, New Jersey
- Kings County Hopsital Center โ Brooklyn, New York
- Coney Island Hospital โ Brooklyn, New York
- Woodhull Hospital โ Brooklyn, New York
- Memorial Sloan Kettering Commack โ Commack, New York
- Memorial Sloan Kettering Westchester โ Harrison, New York
- Queens Hospital Center โ Jamaica, New York
- Memorial Sloan Kettering Cancer Center โ New York, New York
- Memorial Sloan Kettering Nassau โ Uniondale, New York
- Lehigh Valley Health Network โ Allentown, Pennsylvania
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer โ Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer โ Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery โ Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) โ Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer โ Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer โ Duarte, California
Explore by condition: All Breast Cancer clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.